首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal CD3D Antibody

  • 中文名： CD3D抗体
  • 别    名： CD3D; T3D; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD antigen CD3d
货号: IPDX21192
Price： ￥1280
数量：
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 1/20 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 1/50-1/200 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesCD3D; T3D; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD antigen CD3d
Entrez GeneID915
WB Predicted band sizeCalculated MW: 19 kDa; Observed MW: 23 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenRecombinant protein of human CD3D
FormulationPurified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol.

+ +

参考文献

以下是3条关于CD3D抗体的代表性文献摘要(内容为模拟概括，非真实文献)：

1. **"Structural insights into the CD3ε/δ subunits of the T-cell receptor complex"**

- **作者**: Smith A, et al.

- **摘要**: 通过X射线晶体学解析了CD3D与CD3E异源二聚体的结构，揭示了其与T细胞受体(TCR)结合的分子机制，为设计靶向CD3D的抗体提供了结构基础。

2. **"Targeting CD3D in T-cell malignancies: A novel therapeutic approach"**

- **作者**: Chen L, et al.

- **摘要**: 研究开发了一种针对CD3D的单克隆抗体，可特异性识别恶性T细胞表面的CD3D蛋白，通过抗体依赖性细胞毒性(ADCC)抑制T细胞淋巴瘤的进展。

3. **"CD3D deficiency disrupts T-cell development and immune homeostasis"**

- **作者**: Garcia-Sanchez F, et al.

- **摘要**: 利用CD3D基因敲除小鼠模型，揭示了CD3D在T细胞发育和信号转导中的关键作用，并探讨了其缺陷导致的免疫失调机制。

如需具体文献，建议通过PubMed或Google Scholar检索关键词“CD3D antibody”或“CD3D T-cell receptor”获取最新研究。

背景信息

CD3 antibodies target the CD3 complex, a group of transmembrane proteins (CD3ε, γ, δ, ζ) associated with the T-cell receptor (TCR) on T lymphocytes. First identified in the 1980s, CD3 is critical for TCR signaling and T-cell activation. CD3 antibodies primarily bind to the ε subunit (CD3ε), a common epitope across T-cell subsets, making them pan-T cell markers. Therapeutically, anti-CD3 antibodies gained attention with OKT3 (muromonab), the first monoclonal antibody approved in 1986 to prevent organ transplant rejection by transiently depleting T cells. However, OKT3's severe cytokine release syndrome (CRS) limited its use. Modern efforts focus on engineered anti-CD3 antibodies with reduced Fc-mediated activation to minimize toxicity. These include bispecific antibodies (e.g., blinatumomab) that link CD3 to tumor antigens, redirecting T cells against cancers. Additionally, anti-CD3 antibodies are explored in autoimmune diseases (e.g., teplizumab for type 1 diabetes) to modulate pathogenic T cells while preserving immunity. Research continues to optimize their specificity, half-life, and safety, balancing immune activation and tolerance induction. CD3 remains a cornerstone target in immunotherapy due to its central role in adaptive immunity.

客户数据及评论

折叠内容

大包装询价

×